1
|
Das S, Roayapalley PK, Vashishtha SC, Das U, Dimmock JR. Anticonvulsant Properties of 1-Diethylamino-3-phenylprop-2-en-1-one. MEDICINES (BASEL, SWITZERLAND) 2023; 10:54. [PMID: 37755244 PMCID: PMC10535378 DOI: 10.3390/medicines10090054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 07/17/2023] [Accepted: 09/06/2023] [Indexed: 09/28/2023]
Abstract
There is a need for novel antiepileptic agents whose modes of action differ from those of current antiepileptic drugs. The objective of this study was to determine whether 1-diethylamino-3-phenylprop-2-en-1-one (2) could prevent or at least diminish convulsions caused by different mechanisms. This amide afforded protection in the maximal electroshock and subcutaneous pentylenetetrazole screens when given intraperitoneally to both mice and rats. A number of specialized tests in mice were conducted and are explained in the text. They revealed (2) to have efficacy in the 6 Hz psychomotor seizure test, the corneal kindling model, the mouse temporal epilepsy screen and a peripheral neuronal transmission test using formalin. Three screens in rats were undertaken, which revealed that (2) blocked chloride channels, inhibited peripheral neuronal transmission (tested using sciatic ligation and von Frey fibres) and afforded protection in the lamotrigine-resistant kindled rat model. The biodata generated reveal that (2) is an important lead molecule in the quest for novel structures to combat epilepsy.
Collapse
Affiliation(s)
- Swagatika Das
- Drug Discovery and Development Research Group, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada
| | - Praveen K Roayapalley
- Drug Discovery and Development Research Group, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada
| | - Sarvesh C Vashishtha
- Drug Discovery and Development Research Group, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada
| | - Umashankar Das
- Drug Discovery and Development Research Group, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada
| | - Jonathan R Dimmock
- Drug Discovery and Development Research Group, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada
| |
Collapse
|
2
|
Al Rugaie O, Jabir M, Kadhim R, Karsh E, Sulaiman GM, Mohammed SAA, Khan RA, Mohammed HA. Gold Nanoparticles and Graphene Oxide Flakes Synergistic Partaking in Cytosolic Bactericidal Augmentation: Role of ROS and NOX2 Activity. Microorganisms 2021; 9:microorganisms9010101. [PMID: 33466290 PMCID: PMC7824746 DOI: 10.3390/microorganisms9010101] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Revised: 12/28/2020] [Accepted: 12/30/2020] [Indexed: 02/07/2023] Open
Abstract
Gold nanoparticles (GNPs) and graphene oxide flakes (GOFs) exerted significantly (p < 0.0001) supportive roles on the phagocytosis bioactivity of the immune cells of phagocytic nature against the Gram-positive and Gram-negative human pathogenic bacteria Staphylococcus aureus and Escherichia coli. Under experimental conditions, upon bacterial exposure, the combined GNPs and GOFs induced significant clearance of bacteria through phagosome maturation (p < 0.0001) from time-points of 6 to 30 min and production of reactive oxygen species (ROS, p < 0.0001) through the NADPH oxidase 2 (NOX2, p < 0.0001)-based feedback mechanism. The effects of the combined presence of GNPs and GOFs on phagocytosis (p < 0.0001) suggested a synergistic action underway, also achieved through elevated signal transduction activity in the bone-marrow-derived macrophages (BMDM, p < 0.0001). The current study demonstrated that GNPs’ and GOFs’ bactericidal assisting potentials could be considered an effective and alternative strategy for treating infections from both positive and negative bacterial strains.
Collapse
Affiliation(s)
- Osamah Al Rugaie
- Department of Basic Medical Sciences, College of Medicine and Medical Sciences, Qassim University, Unaizah, P.O. Box 991, Al-Qassim 51911, Saudi Arabia;
| | - Majid Jabir
- Department of Applied Sciences, Division of Biotechnology, University of Technology, Baghdad 35010, Iraq; (R.K.); (E.K.)
- Correspondence: (M.J.); (G.M.S.); (S.A.A.M.); Tel.: +964-(0)-7902-781-890 (G.M.S.); +966-(0)-530-309-899 (S.A.A.M.)
| | - Rua Kadhim
- Department of Applied Sciences, Division of Biotechnology, University of Technology, Baghdad 35010, Iraq; (R.K.); (E.K.)
| | - Esraa Karsh
- Department of Applied Sciences, Division of Biotechnology, University of Technology, Baghdad 35010, Iraq; (R.K.); (E.K.)
| | - Ghassan M. Sulaiman
- Department of Applied Sciences, Division of Biotechnology, University of Technology, Baghdad 35010, Iraq; (R.K.); (E.K.)
- Correspondence: (M.J.); (G.M.S.); (S.A.A.M.); Tel.: +964-(0)-7902-781-890 (G.M.S.); +966-(0)-530-309-899 (S.A.A.M.)
| | - Salman A. A. Mohammed
- Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia
- Correspondence: (M.J.); (G.M.S.); (S.A.A.M.); Tel.: +964-(0)-7902-781-890 (G.M.S.); +966-(0)-530-309-899 (S.A.A.M.)
| | - Riaz A. Khan
- Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia; (R.A.K.); (H.A.M.)
| | - Hamdoon A. Mohammed
- Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia; (R.A.K.); (H.A.M.)
- Department of Pharmacognosy, Faculty of Pharmacy, Al-Azhar University, Cairo 11371, Egypt
| |
Collapse
|
3
|
Gunia-Krzyżak A, Żesławska E, Słoczyńska K, Żelaszczyk D, Sowa A, Koczurkiewicz-Adamczyk P, Popiół J, Nitek W, Pękala E, Marona H. S(+)-(2 E)- N-(2-Hydroxypropyl)-3-Phenylprop-2-Enamide (KM-568): A Novel Cinnamamide Derivative with Anticonvulsant Activity in Animal Models of Seizures and Epilepsy. Int J Mol Sci 2020; 21:ijms21124372. [PMID: 32575479 PMCID: PMC7352759 DOI: 10.3390/ijms21124372] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Revised: 06/15/2020] [Accepted: 06/17/2020] [Indexed: 12/03/2022] Open
Abstract
Epilepsy is one of the most frequent neurological disorders affecting about 1% of the world’s human population. Despite availability of multiple treatment options including antiseizure drugs, it is estimated that about 30% of seizures still remain resistant to pharmacotherapy. Searching for new antiseizure and antiepileptic agents constitutes an important issue within modern medicinal chemistry. Cinnamamide derivatives were identified in preclinical as well as clinical studies as important drug candidates for the treatment of epilepsy. The cinnamamide derivative presented here: S(+)-(2E)-N-(2-hydroxypropyl)-3-phenylprop-2-enamide (S(+)-N-(2-hydroxypropyl)cinnamamide, compound KM-568) showed anticonvulsant activity in several models of epilepsy and seizures in mice and rats. It was active in a genetic animal model of epilepsy (Frings audiogenic seizure-susceptible mouse model, ED50 = 13.21 mg/kg, i.p.), acute seizures induced electrically (maximal electroshock test ED50 = 44.46 mg/kg mice i.p., ED50 = 86.6 mg/kg mice p.o., ED50 = 27.58 mg/kg rats i.p., ED50 = 30.81 mg/kg rats p.o., 6-Hz psychomotor seizure model 32 mA ED50 = 71.55 mg/kg mice i.p., 44 mA ED50 = 114.4 mg/kg mice i.p.), chronic seizures induced electrically (corneal kindled mouse model ED50 = 79.17 mg/kg i.p., hippocampal kindled rat model ED50 = 24.21 mg/kg i.p., lamotrigine-resistant amygdala kindled seizure model in rats ED50 = 58.59 mg/kg i.p.), acute seizures induced chemically (subcutaneous metrazol seizure threshold test ED50 = 104.29 mg/kg mice i.p., ED50 = 107.27 mg/kg mice p.o., ED50 = 41.72 mg/kg rats i.p., seizures induced by picrotoxin in mice ED50 = 94.11 mg/kg i.p.) and the pilocarpine-induced status epilepticus model in rats (ED50 = 279.45 mg/kg i.p., ED97 = 498.2 mg/kg i.p.). The chemical structure of the compound including configuration of the chiral center was confirmed by NMR spectroscopy, LC/MS spectroscopy, elemental analysis, and crystallography. Compound KM-568 was identified as a moderately stable derivative in an in vitro mouse liver microsome system. According to the Ames microplate format mutagenicity assay performed, KM-568 was not a base substitution or frameshift mutagen. Cytotoxicity evaluation in two cell lines (HepG2 and H9c2) proved the safety of the compound in concentrations up to 100 µM. Based on the results of anticonvulsant activity and safety profile, S(+)-(2E)-N-(2-hydroxypropyl)-3-phenylprop-2-enamide could be proposed as a new lead compound for further preclinical studies on novel treatment options for epilepsy.
Collapse
Affiliation(s)
- Agnieszka Gunia-Krzyżak
- Jagiellonian University Medical College, Faculty of Pharmacy, Chair of Organic Chemistry, Department of Bioorganic Chemistry, Medyczna 9, 30-688 Kraków, Poland; (D.Ż.); (H.M.)
- Correspondence:
| | - Ewa Żesławska
- Pedagogical University, Institute of Biology, Podchorążych 2, 30-084 Kraków, Poland;
| | - Karolina Słoczyńska
- Jagiellonian University Medical College, Faculty of Pharmacy, Department of Pharmaceutical Biochemistry, Medyczna 9, 30-688 Kraków, Poland; (K.S.); (A.S.); (P.K.-A.); (J.P.); (E.P.)
| | - Dorota Żelaszczyk
- Jagiellonian University Medical College, Faculty of Pharmacy, Chair of Organic Chemistry, Department of Bioorganic Chemistry, Medyczna 9, 30-688 Kraków, Poland; (D.Ż.); (H.M.)
| | - Aleksandra Sowa
- Jagiellonian University Medical College, Faculty of Pharmacy, Department of Pharmaceutical Biochemistry, Medyczna 9, 30-688 Kraków, Poland; (K.S.); (A.S.); (P.K.-A.); (J.P.); (E.P.)
| | - Paulina Koczurkiewicz-Adamczyk
- Jagiellonian University Medical College, Faculty of Pharmacy, Department of Pharmaceutical Biochemistry, Medyczna 9, 30-688 Kraków, Poland; (K.S.); (A.S.); (P.K.-A.); (J.P.); (E.P.)
| | - Justyna Popiół
- Jagiellonian University Medical College, Faculty of Pharmacy, Department of Pharmaceutical Biochemistry, Medyczna 9, 30-688 Kraków, Poland; (K.S.); (A.S.); (P.K.-A.); (J.P.); (E.P.)
| | - Wojciech Nitek
- Jagiellonian University, Faculty of Chemistry, Gronostajowa 2, 30-387 Kraków, Poland;
| | - Elżbieta Pękala
- Jagiellonian University Medical College, Faculty of Pharmacy, Department of Pharmaceutical Biochemistry, Medyczna 9, 30-688 Kraków, Poland; (K.S.); (A.S.); (P.K.-A.); (J.P.); (E.P.)
| | - Henryk Marona
- Jagiellonian University Medical College, Faculty of Pharmacy, Chair of Organic Chemistry, Department of Bioorganic Chemistry, Medyczna 9, 30-688 Kraków, Poland; (D.Ż.); (H.M.)
| |
Collapse
|